Gene therapy for hereditary hearing loss.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing preclinical and early clinical gene therapy applications
PubMed 39616957 · doi:10.1016/j.heares.2024.109151
What was done
The authors conducted a narrative review summarizing gene therapy strategies for hereditary hearing loss. They evaluated gene-editing mechanisms such as CRISPR/Cas systems, delivery platforms emphasizing adeno-associated virus vectors, inner ear administration routes, animal model findings, and preliminary clinical trial applications in pediatric populations.
What was found
The abstract reports that genetic factors account for approximately 50% of profound hearing loss cases, with over 150 independent genes identified. Preclinical studies demonstrate that adeno-associated virus vectors safely and efficiently deliver transgenes to inner ear cells, and early applications have restored hearing in some children with hereditary deafness. No specific quantitative outcome data or sample sizes are reported in the abstract.
Why it matters
Hereditary hearing loss is a common sensory disorder with limited biological treatment options. This review synthesizes progress in moving inner ear gene-editing tools and viral delivery systems toward clinical application.
Limits
The paper is a narrative review without systematic search protocols, risk of bias assessments, or quantitative pooling. The abstract lacks numerical efficacy metrics. Significant clinical translation barriers remain, including genetic heterogeneity across more than 150 target genes, delivery vector limitations, and challenges in inner ear administration.
Cited by
- supports More than 200 distinct genes have been identified as causes of human hearing loss.